[go: up one dir, main page]

BE622943A - Compositions thérapeutiques, contenant des dérivés d'émétine. - Google Patents

Compositions thérapeutiques, contenant des dérivés d'émétine.

Info

Publication number
BE622943A
BE622943A BE622943A BE622943A BE622943A BE 622943 A BE622943 A BE 622943A BE 622943 A BE622943 A BE 622943A BE 622943 A BE622943 A BE 622943A BE 622943 A BE622943 A BE 622943A
Authority
BE
Belgium
Prior art keywords
therapeutic compositions
emetine
derivatives
emetine derivatives
therapeutic
Prior art date
Application number
BE622943A
Other languages
English (en)
Inventor
W H Linnell
J H Chapman
Original Assignee
Glaxo Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Lab Ltd filed Critical Glaxo Lab Ltd
Publication of BE622943A publication Critical patent/BE622943A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D455/00Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/04Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
    • C07D455/06Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine containing benzo [a] quinolizine ring systems
    • C07D455/08Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine containing benzo [a] quinolizine ring systems having an isoquinolyl-1, a substituted isoquinolyl-1 or an alkylenedioxyisoquinolyl-1 radical linked through only one carbon atom, attached in position 2, e.g. emetine
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08FMACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00Chemical modification by after-treatment
    • C08F8/26Removing halogen atoms or halogen-containing groups from the molecule
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BE622943A 1961-09-29 1962-09-27 Compositions thérapeutiques, contenant des dérivés d'émétine. BE622943A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB35268/61A GB982150A (en) 1961-09-29 1961-09-29 Therapeutic resin complexes

Publications (1)

Publication Number Publication Date
BE622943A true BE622943A (fr) 1963-01-16

Family

ID=10375806

Family Applications (1)

Application Number Title Priority Date Filing Date
BE622943A BE622943A (fr) 1961-09-29 1962-09-27 Compositions thérapeutiques, contenant des dérivés d'émétine.

Country Status (3)

Country Link
BE (1) BE622943A (fr)
FR (1) FR2489M (fr)
GB (1) GB982150A (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4076804A (en) * 1975-07-18 1978-02-28 Abbott Laboratories Erythromycin therapy
FI65910C (fi) * 1976-11-26 1984-08-10 Pennwalt Corp Foerfarande foer framstaellning av farmaceutiska preparat med laongtidsverkan
US4859462A (en) * 1986-07-30 1989-08-22 Fisons Corporation Polymer-treated ion exchange resins
US4859461A (en) * 1986-07-30 1989-08-22 Fisons Corporation Coatable ion exchange resins
NZ219925A (en) * 1986-07-30 1989-06-28 Pennwalt Corp Polymer-treated sulphonic acid cationic exchange resin particles
IE62100B1 (en) * 1986-07-30 1994-12-14 Fisons Corp Coated ion exchange resins
CA2002492A1 (fr) * 1988-11-11 1990-05-11 Sandra T. A. Malkowska Compose pharmaceutique contenant une resine echangeuse d'ions
WO2006081518A2 (fr) * 2005-01-28 2006-08-03 Collegium Pharmaceutical, Inc. Excipients non aqueux non ioniques pour administration topique et par voie orale d'agents actifs lies a un support

Also Published As

Publication number Publication date
GB982150A (en) 1965-02-03
FR2489M (fr) 1964-04-27

Similar Documents

Publication Publication Date Title
BE622943A (fr) Compositions thérapeutiques, contenant des dérivés d'émétine.
FR2144M (fr) Compositions pharmaceutiques contenant des sources radioactives.
DK103662C (da) Herreunderbenklæder.
FR1902M (fr) Nouveaux médicaments dérivés de l'isothiazole.
FR2517M (fr) Compositions pharmaceutiques contenant des propanolamines.
FR6247M (fr) Nouvelles applications thérapeutiques des épithio-2,3 stéroïdes.
FR2075M (fr) Nouveaux dérivés de la 6-méthyl- et de la 1,6-diméthyl-ergoline i.
BE601304A (fr) Compositions stables contenant de l'isoprotéronol.
FR2247M (fr) Nouvelles compositions médicamenteuses contre l'aphte.
FR2477M (fr) Dérivés aminés des n-cyclopropylbenzylamines.
BE626351A (fr) Compositions contenant une 2,6-dichlorobenzamidine comme ingrédient actif
FR3173M (fr) Dérivés thérapeutiques d'aralcoyl-2-mercapto-benzazoles.
FR2849M (fr) Composition pour soins dentaires.
FR3461M (fr) Nouvelles compositions médicamenteuses contenant des dérivés de l'acétyl-glutamine.
FR2260M (fr) Dérivés de la 16 alpha-chloroprednisolone et compositions thérapeutiques en contenant.
BE619267A (fr) Dérivés d'algines dépolymérisées.
FR2985M (fr) Compositions pharmaceutiques contenant des dérivés de l'indole.
FR2395M (fr) Compositions thérapeutiques contenant du 3,5-diméthylisoxazole.
FR2156M (fr) Nouvelles compositions thérapeutiques.
FR1722M (fr) Médicaments nouveaux constitués par des 4-(pyridoylamido-acylamino)-1-phényl-2,3-diméthyl-pyrazolones-(5).
FR1373M (fr) Composition thérapeutique.
OA00656A (fr) Compositions contenant des dérivés alkylés de la phlorophénone.
FR2398M (fr) Compositions provoquant l'anorexie.
BE585967A (fr) Compositions pharmaceutiques contenant des dérivés de la benzylhydrazine.
FR1777M (fr) Médicament contenant des préparations contre l'hypertension.